Abstract
Background: Chronic pain is treated most commonly with opioid analgesics, anti-inflammatory steroids and nonsteroidal anti-inflammatory drugs.
Method: However, these compounds are not uniformly effective and their clinical use is constrained by unwanted side effects. GABAergic neurons are located in spinal nociceptive circuits suggesting that drugs with affinity at these receptors, including benzodiazepine-like drugs, may provide an alternative to opioids for the treatment of pain. However, systemically administered conventional benzodiazepines fail to produce antihyperalgesic effects, likely due to their concurrent sedative properties. Results: Recent evidence suggests that by targeting specific benzodiazepine-sensitive GABAA receptor subtypes, the sedative properties of benzodiazepines can be circumvented and these compounds may be useful alternatives to opioids for the treatment of chronic pain. Conclusion: The present review provides an overview of the GABAA receptor subtypes involved in pain transmission as well as implications for the development of analgesic medications.Keywords: Antihyperalgesic, benzodiazepine, drug development, disorders, GABAA, pain.
CNS & Neurological Disorders - Drug Targets
Title:GABAA Receptors as Targets for the Management of Pain-related Disorders: Historical Perspective and Update
Volume: 16 Issue: 6
Author(s): Bradford D. Fischer*
Affiliation:
- Cooper Medical School of Rowan University, Camden, NJ,United States
Keywords: Antihyperalgesic, benzodiazepine, drug development, disorders, GABAA, pain.
Abstract: Background: Chronic pain is treated most commonly with opioid analgesics, anti-inflammatory steroids and nonsteroidal anti-inflammatory drugs.
Method: However, these compounds are not uniformly effective and their clinical use is constrained by unwanted side effects. GABAergic neurons are located in spinal nociceptive circuits suggesting that drugs with affinity at these receptors, including benzodiazepine-like drugs, may provide an alternative to opioids for the treatment of pain. However, systemically administered conventional benzodiazepines fail to produce antihyperalgesic effects, likely due to their concurrent sedative properties. Results: Recent evidence suggests that by targeting specific benzodiazepine-sensitive GABAA receptor subtypes, the sedative properties of benzodiazepines can be circumvented and these compounds may be useful alternatives to opioids for the treatment of chronic pain. Conclusion: The present review provides an overview of the GABAA receptor subtypes involved in pain transmission as well as implications for the development of analgesic medications.Export Options
About this article
Cite this article as:
Fischer D. Bradford*, GABAA Receptors as Targets for the Management of Pain-related Disorders: Historical Perspective and Update, CNS & Neurological Disorders - Drug Targets 2017; 16 (6) . https://dx.doi.org/10.2174/1871527316666170207155149
DOI https://dx.doi.org/10.2174/1871527316666170207155149 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advances in Hydrogels Applied to Degenerative Diseases
Current Pharmaceutical Design Pilot Study of Eyesight Characteristics and Thickness of the Retinal Nerve Fiber and Ganglion Cell-inner Plexiform Layers in Adolescent Patients with Type one Diabetes Mellitus on an Insulin Pump
Current Pharmaceutical Design Clinical Application of Ghrelin
Current Pharmaceutical Design Endothelial Nitric Oxide Synthase Gene Therapy for Erectile Dysfunction
Current Pharmaceutical Design Hepatocyte Growth Factor (HGF): Neurotrophic Functions and Therapeutic Implications for Neuronal Injury/Diseases
Current Signal Transduction Therapy Cellular and Molecular Mechanisms of Dementia: Decoding the Causal link of Diabetes Mellitus in Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Inflammatory Markers Associated With Diabetes Mellitus – Old and New Players
Current Pharmaceutical Design Early Risk Factors for Nonadherence in Pediatric Type 1 Diabetes: A Review of the Recent Literature
Current Diabetes Reviews Neurotrophic Factors - A Tool for Therapeutic Strategies in Neurological,Neuropsychiatric and Neuroimmunological Diseases?
Current Medicinal Chemistry Development of Aldose Reductase Inhibitors for the Treatment of Inflammatory Disorders and Cancer: Current Drug Design Strategies and Future Directions
Current Medicinal Chemistry Renal Nerve Ablation for Hypertensive Patients with Chronic Kidney Disease
Current Vascular Pharmacology Trypanosomatid Parasites Causing Neglected Diseases
Current Medicinal Chemistry Effects of Metabolic Approach in Diabetic Patients with Coronary Artery Disease
Current Pharmaceutical Design Dicarbonyls Generation, Toxicities, Detoxifications and Potential Roles in Diabetes Complications
Current Protein & Peptide Science Mitochondrial Toxicity in HAART: An Overview of In Vitro Evidence
Current Pharmaceutical Design NF-κB Blockers Gifted by Mother Nature: Prospectives in Cancer Cell Chemosensitization
Current Pharmaceutical Design Chalcone Derivatives Activate and Desensitize the Transient Receptor Potential Ankyrin 1 Cation Channel, Subfamily A, Member 1 TRPA1 Ion Channel: Structure-Activity Relationships in vitro and Anti-Nociceptive and Anti-inflammatory Activity in vivo
CNS & Neurological Disorders - Drug Targets Integrative Control of Gastrointestinal Motility by Nitric Oxide
Current Medicinal Chemistry Therapeutic Potential of Caffeic Acid Phenethyl Ester (CAPE) in Diabetes
Current Medicinal Chemistry Mitochondrial Aldehyde Dehydrogenase, A Potential Drug Target for Protection of Heart and Brain from Ischemia/Reperfusion Injury
Current Drug Targets